Dr. Mei Mei Tian is a vice president and the head of external research at Bioasis Technologies, Inc. Dr. Tian has more than 10 years of experience working on melanotransferrin-related research in both academia and biotech. At the University of British Columbia, she investigated the role of melanotransferrin in melanoma malignancy, as well as mechanisms involved in melanotransferrin uptake in cells.
Since joining the Bioasis team in 2012, she has been a significant contributor in the early development and continued expansion of our proprietary blood-brain barrier technology, xB3. With her oncology and neurology background, she is a committed and driven individual with a passion for the success of our platform.
Dr. Tian received her doctor of philosophy degree in microbiology and immunology from the University of British Columbia.